Most Women Enter Menopause in the Dark: New Survey Reveals Stark Gaps in Hormone Health Education
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- The HRT Club, a leading pioneer of direct-to-consumer hormone replacement therapies, today unveiled findings from a national survey of 1,000 women aged 45-60, uncovering a widespread crisis in menopause education and care. The results show that most women in the U.S. are entering this major life stage underinformed, underserved and unsupported with limited access to accurate information, treatment options or doctors who take their symptoms seriously.
According to the data, 86% of women are not fully confident in their understanding of the menopausal journey and 84% say they don't feel adequately informed about available treatments.
Share
According to the data, 86% of women are not fully confident in their understanding of the menopausal journey and 84% say they don't feel adequately informed about available treatments. 60% of women didn't learn about menopause until they were already in it. Compounding the issue, 70.5% say their doctor was not fully adequate in preparing them for menopause or discussing treatment options.
Menopause disrupts every aspect of daily life
The survey also revealed the profound effects menopause has on day-to-day life:
73.1% of women report disrupted sleep, with 86.9% citing trouble falling or staying asleep and 68% impacted by night sweats.
44.6% say menopause has negatively affected their relationships with 83.2% reporting a diminished sex drive and 60% experiencing mood swings.
11.6% say their career growth has taken a hit, due to issues like workplace distraction from hot flashes (57.5%) and strained colleague relationships (68.5%).
Overall, 72.1% say they 'don't feel like themselves,' due to weight gain (57.4%) and aging appearance (51.6%).
'We're witnessing a healthcare blind spot,' said Lauren Darisse, COO and General Counsel of The HRT Club. 'Menopause impacts half the population, yet it's often ignored, mischaracterized and left out of mainstream medical conversations. We believe women deserve better and we're here to make that happen.'
A powerful treatment still out of reach for too many women
Hormone replacement therapy (HRT), when prescribed by experienced providers, can be life-changing, yet it remains widely misunderstood and underutilized. Just 13.5% of women feel deeply familiar with HRT. While nearly 30% learned about it from a healthcare provider, 21.9% had to turn to online research. Even then, 50.8% report being left confused by conflicting information and just 13.8% feel confident in their understanding of HRT's potential benefits.
For those who do use HRT, the results are encouraging:
76.5% say HRT got their life back on track.
63.9% reported symptom relief within two months.
Among current users, 87.4% report a strong positive impact.
Yet access remains a barrier. More than 66% of women believe HRT should be more affordable, as over 25% of users have stopped treatment due to cost and more than 40% struggled to get HRT covered by their insurance at all.
A new standard of care
The HRT Club is making hormone health easier than ever with access to affordable treatments and HRT-knowledgeable, U.S. physician experts. By offering affordable, physician-prescribed treatments and personalized care plans via a direct-to-consumer platform, The HRT Club is making hormone health easier to access and easier to understand. By providing access to licensed U.S. physician experts and science-backed education, The HRT Club is on a mission to demystify menopause and give women back control of their health, their confidence and their lives.
Learn more about how The HRT Club is redefining the future of hormonal care at https://thehrtclub.com.
Methodology
The HRT Club commissioned a nationwide survey with Propeller Insights, polling 1,000 U.S. women aged 45 to 60 in April 2025 to evaluate their knowledge, perceptions and experiences surrounding menopause, hormone replacement therapy and access to care.
About Propeller Insights
Propeller Insights is a full-service market research firm based in Los Angeles. Using quantitative and qualitative methodologies to measure and analyze marketplace and consumer opinions, they work extensively across industries such as travel, brand intelligence, entertainment/media, retail and consumer packaged goods.
About The HRT Club
The HRT Club is on a mission to make hormonal treatments accessible to everyone. Since its launch in April 2024, The HRT Club has quickly become the leading doctor-recommended platform for hormone replacement therapy (HRT). With a network of over 1,300 prescribers and strategic partnerships across the healthcare industry, we are transforming how people access and afford hormonal treatments. Our members enjoy savings of up to 90% on their HRT prescriptions, ensuring that life-changing care is within reach for all who need it. For more information, visit https://thehrtclub.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
ICD 2025: New data demonstrate Nemluvio ® 's (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) today announced data from a new interim analysis of a study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis. The new data show Nemluvio is well tolerated and associated with sustained and clinically meaningful improvements in symptoms including itch and skin lesions, during prolonged treatment up to two years. 1 These new data will be presented as a late-breaking session at ICD, on Saturday, June 21, 2025 at 08:30 AM CET. Prurigo nodularis is a chronic, debilitating, and distinct neuroimmune skin disease characterized by the presence of intense itch and thick skin nodules, which have a substantial impact on patients' quality of life. 5-7 Nemluvio is the first approved monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-31. 8,9,10 IL-31 is a neuroimmune cytokine that drives itch and is involved in inflammation, skin barrier dysfunction, and fibrosis in prurigo nodularis. 8-11 It is also the first and only biologic approved for prurigo nodularis as well as atopic dermatitis with four-week dosing intervals from the start of treatment. 9,10 The OLYMPIA long-term extension study was designed to assess the safety and efficacy of Nemluvio in patients with prurigo nodularis up to four years and includes 508 patients from the phase II trial or the phase III OLYMPIA 1 and 2 trials. 1 Results show that treatment with Nemluvio is associated with sustained and clinically meaningful improvements in symptoms of prurigo nodularis during prolonged treatment up to two years. 1 At Week 100 in evaluable patients, the interim analysis shows that: More than 90% and 70% achieved at least a four-point improvement in itch, and being itch free or nearly itch free respectively, as measured by the Peak-Pruritus Numerical Rating Scale 1 At least 80% achieved 76‑100% healed pruriginous lesions 1 Approximately 75% reached clearance or almost-clearance of skin nodules when assessed using the Investigator's Global Assessment score 1 Nemluvio was well tolerated in the long-term treatment of prurigo nodularis and no new safety signals were identified in this study to date. 1 'These impressive results give us even more confidence in the value of nemolizumab – a much-needed innovative medicine that has the potential to deeply impact the prurigo nodularis treatment landscape. With this new treatment now approved in multiple markets including the EU and U.S., I'm thrilled to be able to see its meaningful impact in the real world.' PROF. SONJA STÄNDER Expand This follows presentation of results from the ARCADIA long-term extension study at the RAD Conference earlier this month, which showed that treatment with Nemluvio was well tolerated and associated with sustained and increased improvements in symptoms of atopic dermatitis during prolonged treatment up to two years. 4 Nemluvio was first approved in August 2024 by the United States Food and Drug Administration (U.S. FDA) for the treatment of adults with prurigo nodularis. 9 In December 2024, it was also approved by the U.S. FDA for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies. 9 To date, Nemluvio is approved for both moderate-to-severe atopic dermatitis and prurigo nodularis by multiple regulatory authorities around the world, including the European Commission. Additional reviews and submissions are ongoing. Galderma will also host a symposium at ICD, exploring the latest advances in addressing itch in both prurigo nodularis and atopic dermatitis. Separately, the company will share new data from across its Therapeutic Dermatology portfolio in acne, non-melanoma skin cancer, and rosacea. More details on Galderma's scientific presentations at ICD can be found here. About Nemluvio Nemluvio was initially developed by Chugai Pharmaceutical Co., Ltd. In 2016, Galderma obtained exclusive rights to the development and marketing of nemolizumab worldwide, except in Japan. In Japan, nemolizumab is marketed as Mitchga ® and is approved for the treatment of prurigo nodularis, as well as pruritus associated with atopic dermatitis in pediatric, adolescent, and adult patients. 12,13 About prurigo nodularis Prurigo nodularis is a chronic, debilitating, and distinct neuroimmune skin disease characterized by the presence of intense itch and thick skin nodules covering large body areas. 5-7 It is an underrecognized and underdiagnosed skin condition, and there are limited studies investigating its prevalence. 11,14,15 About Galderma Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: References Ständer S, et a. Nemolizumab long-term efficacy and safety up to 100 weeks in the OLYMPIA open-label extension study in patients with prurigo nodularis: An interim analysis. Presented at International Congress of Dermatology; June 18-21, 2025; Rome, Italy. A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) (NCT04501679). Available online. Accessed May 2025 Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) (NCT04501666). Available online. Accessed May 2025 Silverberg, JI, et al. Nemolizumab long-term safety and efficacy up to 104 weeks in the ARCADIA open-label extension study in adolescents and adults with moderate-to-severe atopic dermatitis. Presented at Revolutionizing Atopic Dermatitis Conference 2025; June 6-7; Nashville, United States. Huang AH, et al. Prurigo nodularis: epidemiology and clinical features. J Am Acad Dermatol. 2020;83(6):1559-1565. doi: 10.1016/ Pereira MP, et al. European Academy of Dermatology and Venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol. 2018;32(7):1059-1065. doi: 10.1111/jdv.14570 Ständer S, et al. IFSI-guideline on chronic prurigo including prurigo nodularis. Itch. 2020;5(4):e42. doi: 10.1097/itx.0000000000000042 Silverberg JI, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145(1):173-182. doi: 10.1016/ Nemluvio U.S. Prescribing Information. Available online. Accessed May 2025 Nemluvio European Medicines Agency. Summary of Product Characteristics. Available online. Accessed May 2025 Bewley A, et al. Prurigo Nodularis: A Review of IL-31RA Blockade and Other Potential Treatments. Dermatol Ther (Heidelb). 2022;12(9):2039–2048. doi: 10.1007/s13555-022-00782-2 Chugai Pharmaceutical Co., Ltd. Maruho Obtained Regulatory Approval for Mitchga, the first Antibody Targeting IL-31 for Itching Associated with Atopic Dermatitis. Available online. Accessed May 2025 Chugai Pharmaceutical Co., Ltd. Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials. Available online. Accessed May 2025 Ständer S, et al. Prevalence of prurigo nodularis in the United States of America: a retrospective database analysis. JAAD Int. 2020;2:28-30. doi: 10.1016/ Huang AH, et al. Real-world prevalence of prurigo nodularis and burden of associated diseases. J Invest Dermatol.
Business Wire
8 hours ago
- Business Wire
Align Technology Launches Integrated Consumer and Professional Brand Campaign Focused on Invisalign ® Treatment for Kids and Teens
TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. ('Align') (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign ® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced integrated global professional and consumer campaigns to highlight the unique needs of growing patients and treatment options for meeting those needs and creating new smiles with the Invisalign clear aligner system. As the leader in digital orthodontics, Align has developed an extensive end-to-end portfolio that helps doctors treat a range of case types including the most complex cases, and growing patients and kids as young as 6. Share 'We are proud to launch these complementary Invisalign ® brand campaigns about the kid and teen-friendly orthodontic solutions from the #1 doctor-recommended clear aligner brand, 1 ' said Kamal Bhandal, senior vice president, Global Brand, Consumer and Americas Marketing. 'Our new 'Invisalign for Kids' brand consumer campaign is designed to increase awareness with parents that Invisalign aligners are an effective solution for kids and educate parents about the benefits of Invisalign treatment for kids and teens, including Invisalign ® Palatal Expander System, Invisalign First™, Invisalign ® System with mandibular advancement, as well as Invisalign ® Virtual Care to help parents monitor progress – all designed to deliver predictable results and a positive experience for growing children.' The aspects of Invisalign treatment, from Phase 1 to comprehensive Phase 2, to retention are designed for predictable results and a positive experience while addressing the unique needs of growing children. And with Invisalign aligners, children can enjoy their favorite foods, keep up their oral hygiene, maintain an active lifestyle, and smile and build their confidence. At the same time, our companion Invisalign 'Growing Patients' professional campaign provides doctors with information and awareness about the dedicated range of Invisalign treatment options designed specifically for children and teens from well-established products such as Invisalign First™ aligners to the latest additions in the growing patient product portfolio, including the Invisalign ® Palatal Expander System and Invisalign ® System with mandibular advancement featuring occlusal blocks ('MAOB'). Doctors can use the Invisalign System to treat nearly any orthodontic case, from children through teens to adults, at the different stages of their growth. Even with some baby teeth, it may be the perfect time for children ages 6 to 10 to start Phase 1 orthodontic treatment. According to the American Association of Orthodontists ('AAO'), children should get screened by an orthodontist by age 7. 2 Phase 1 treatment takes advantage of a child's normal development to help bones in the face and mouth grow correctly and reduce the need for more extensive treatment later. Once most permanent teeth are in place, Phase 2 treatment focuses on ensuring teeth are in their proper place for a healthy bite and a pleasing appearance. 3 'As kids and teens age and grow, orthodontic treatment needs to address both tooth movement and dental facial orthopedic or skeletal movement,' said Dr. Mitra Derakhshan, executive vice president, chief clinical officer, Global Treatment Planning and Clinical Services. 'As the leader in digital orthodontics, Align has developed an extensive end-to-end portfolio that helps doctors treat a range of case types including the most complex cases, and growing patients and kids as young as 6. I believe our new 'Invisalign for Kids' brand and 'Growing Patients' campaigns will help increase confidence in Invisalign treatment for the largest segment of the orthodontic market and drive further adoption among growing patients.' This latest announcement is part of Align's long-term investment in the growing patients' segment of the market which has included multiple innovation milestones over 20 million smiles. Overview of Invisalign products for growing patients: 2008: Invisalign ® Teen – Teen specific features to address patient compliance, natural eruption of permanent teeth, and root-movement control – issues that are common in treatment of younger patients. 2017: Invisalign ® System with mandibular advancement – the first clear aligner solution designed for simultaneous Class II correction and alignment in growing tween and teen patients and Invisalign ® System with mandibular advancement featuring enhanced precision wings. 2018: Invisalign First™ – the first clear aligner treatment with features designed specifically to address a broad range of indications in mixed-dentition patients, including shorter clinical crowns, management of erupting dentition, and predictable dental arch expansion. 2023: Invisalign ® Palatal Expander System –Align's first direct 3D printed orthodontic device, provides a safe, comfortable, and clinically effective 4 alternative to traditional palatal expanders that require manually turning a screw in the device in the mouth daily to achieve skeletal expansion. 2025: Invisalign ® System with mandibular advancement featuring occlusal blocks – Align's first clear aligner product with integrated solid occlusal blocks that delivers predictable mandibular advancement. Invisalign occlusal blocks provide durability, improve engagement, and enable vertical opening to offer earlier advancement of the mandible in cases like Class II deep bite to improve treatment efficiency. 'Our commitment is to support our doctors in treating patients through every step of their journey – from first visit to a lasting smile. More than 28 years of anonymized data from more than 20 million Invisalign ® patients treated globally have helped Align develop our integrated suite of innovative products and solutions that enable doctors to treat patients over their continuum of care,' said Michael Smith, Align vice president, Product Management. 'This new integrated campaign highlights the unique product offerings within our growing patient portfolio and how we are innovating in digital orthodontics to empower doctors to transform smiles and change lives.' 1. Based on a global survey of 1,786 doctors (dentists and orthodontists who use clear aligners) by IQVIA in NA, EMEA, LATAM, and APAC. Data on File at Align Technology, as of June 30, 2022. 2. American Academy of Orthodontists. The Right Time: When Should Your Child See an Orthodontist? ( Accessed 2/26/24. 3. American Academy of Orthodontists. Embarking on a Two Phase Orthodontic Adventure ( Accessed 2/28/24. 4. Based on a survey in August 2023 in Canada of 10 Invisalign trained orthodontists who participated in the Invisalign Palatal Expander System Technical Design Assessment and have treated at least 1 patient age 6-11 years with IPE. Data on file at Align Technology, Inc. as of October 30, 2023. About Align Technology, Inc. Align Technology designs and manufactures the Invisalign ® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 281.4 thousand doctor customers and are key to accessing Align's 600 million consumer market opportunity worldwide. Over the past 28 years, Align has helped doctors treat over 20.1 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit for more information. For additional information about the Invisalign System or to find an Invisalign doctor in your area, please visit For additional information about the iTero digital scanning system, please visit For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit Invisalign, iTero, exocad, Align, Align Digital Platform and iTero Lumina are trademarks of Align Technology, Inc.
Business Wire
10 hours ago
- Business Wire
Scholarships to 85 Students Pursuing Careers in Healthcare
VICTORVILLE, Calif.--(BUSINESS WIRE)--The Dr. Prem Reddy Family Foundation presented $110,000 in academic scholarships to 85 outstanding and diverse High Desert students pursuing careers in health sciences during its annual ceremony Thursday in Victorville. Thursday's event was the latest in the Foundation's decades-long mission to encourage and support the newest generation of healthcare professionals. To date, the Foundation has awarded more than $2 million in scholarships. 'The event was more than a celebration of achievement—it was a tribute to the passion and purpose it takes to pursue a calling in healthcare,' said Sunitha Reddy, Executive Director. 'These scholars are the reason this Foundation exists. Through their commitment to serve, they carry forward a legacy grounded in compassion, access, and hope.' This year's scholarship recipients ranged in age from 16 to 54, including high school students overcoming adversity and single mothers returning to school. A record number of applications were received in 2025, reflecting both increased need and interest in healthcare careers. 'You've chosen a path in healthcare, a path that demands knowledge, compassion, and resilience,' said Sunitha Reddy. 'As you care for others, never forget that your journey is part of a greater legacy, one rooted in service and driven by the belief that every patient deserves to be seen, heard, and healed.' Among the recipients was Tiffany Bogan, who shared her powerful personal journey. Born with neonatal abstinence syndrome and placed in foster care, she later survived Hurricane Katrina and faced continued hardship from addiction and loss in her family. "I'm not here because everything went right—I'm here because I never gave up,' Bogan said. 'I've built this future from the ground up, and I plan to use it to serve others as a doctor, shaped by struggle and led by love." The keynote address was delivered by Karyl James, Chief Nursing Officer at Desert Valley Hospital, who spoke on perseverance, purpose, and service in healthcare. 'As you stand at the crossroads of your journey in healthcare, remember that your path is not just about the destination—it's about the lives you touch, the lessons you learn, and the growth you experience along the way,' she said. Founded in 1989 by Dr. Prem Reddy, Founder, Chairman and CEO of Prime Healthcare, the Foundation supports scholarships, health education, public health programs, and community clinics locally and globally. The list of speakers and presenters included: Sunitha Reddy, MBA, MPH, FACHE, Executive Director of the Dr. Prem Reddy Family Foundation Dr. Venkamma Reddy, Co-Founder of the Dr. Prem Reddy Family Foundation Karyl James, DNP, MSN, RN, Chief Nursing Officer at Desert Valley Hospital Tiffany Bogan, 2025 Dr. Prem Reddy Family Foundation Scholarship recipient Elizabeth Becerra, Mayor, Victorville Representatives and citations from the offices of U.S. Congressman Jay Obernolte, State Senator Suzette Valladares, and Assemblyman Tom Lackey Marie Langley, MBA, FACHE, Chief Executive Officer, Desert Valley Medical Group The High Desert is designated as a Health Professional Shortage Area, with many recipients expressing a commitment to serve locally. To address physician shortages across the Inland Empire, Dr. Reddy and the Foundation helped establish the California University of Science and Medicine (CUSM) with a contribution exceeding $80 million. CUSM graduated its first class of 62 physicians in 2022, many of whom plan to serve the region. About the Dr. Prem Reddy Family Foundation The Dr. Prem Reddy Family Foundation, founded by Dr. Prem Reddy and his family, has donated millions in support of health education, college scholarships, public healthcare education, and free community clinics. On a global level, the foundation supports Samaritan's Purse by donating equipment used in clinics in poverty-stricken regions around the world. The foundation also funds clean water initiatives, childhood vaccinations programs, educational grants, new medical clinics, and medical missions. For more information, visit
